Oruka Therapeutics, Inc. (ORKA) Earnings History
Annual and quarterly earnings data from 2005 to 2024
Loading earnings history...
ORKA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ORKA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
Download Data
Export ORKA earnings history in CSV or JSON format
Free sign-in required to download data
Oruka Therapeutics, Inc. (ORKA) Earnings Overview
As of May 8, 2026, Oruka Therapeutics, Inc. (ORKA) reported trailing twelve-month net income of -$109M, reflecting +39.7% year-over-year growth. The company earned $-2.48 per diluted share over the past four quarters.
Looking at the long-term picture, ORKA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$4M in fiscal 2012.
Oruka Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including REGN ($4.42B net income, 31.4% margin), SANA (-$234M net income), ARQT (-$2M net income, -4.3% margin), ORKA has comparable earnings metrics. Compare ORKA vs REGN →
ORKA Earnings vs Peers
Earnings metrics vs comparable public companies
ORKA Historical Earnings Data (2005–2024)
19 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$84M | -743.5% | -$88M | $-4.99 | - | - |
| 2022 | -$10M | +48.6% | -$10M | $-8.27 | - | - |
| 2021 | -$19M | -98.4% | -$19M | $-16.68 | - | - |
| 2020 | -$10M | -77.6% | -$10M | $-8.40 | - | - |
| 2019 | -$5M | +30.9% | -$6M | $-49.79 | - | - |
| 2018 | -$8M | +57.1% | -$8M | $-123.73 | - | - |
| 2017 | -$18M | -12.4% | -$19M | $-382.87 | - | - |
| 2016 | -$16M | -43.7% | -$17M | $-390.96 | - | - |
| 2015 | -$11M | -18.1% | -$11M | $-393.12 | - | - |
| 2014 | -$10M | -39.6% | -$10M | $-710.64 | - | - |
See ORKA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ORKA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ORKA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonORKA — Frequently Asked Questions
Quick answers to the most common questions about buying ORKA stock.
Is ORKA growing earnings?
ORKA EPS is $-2.48, with earnings growth accelerating to +39.7%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-109M.
What are ORKA's profit margins?
Oruka Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are ORKA's earnings?
ORKA earnings data spans 2005-2024. The accelerating earnings trend is +39.7% YoY. Historical data enables comparison across business cycles.